Korean Biopharma Today And Tomorrow: M&A, Investment, Governance

Policies, Family Management In Spotlight

Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes. 

Korea Bioplus Interphex
M&A The Biggest Keyword For Korean Biopharmas In Next Decade • Source: Jung Won Shin

The South Korean biopharma industry has come a long way in the past couple of decades. Global out-licensing deals surged more than 21% from just 2020 to 2021 and the country has witnessed the development of its 34th original new drug, contrasting from a time when it was not able to develop any innovative products.

Meanwhile, the number of bioventures has risen to 3,000, while companies such as Samsung BioLogics and Celltrion, Inc....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia